An Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study

BACKGROUND: Although Alzheimer’s disease affects around 800,000 people in the UK and costs almost £23 billion per year, currently licenced treatments only offer modest benefit at best. Seizures, which are more common in patients with Alzheimer’s disease than age matched controls, may contribute to t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Trials
Main Authors: Sen, Arjune, Akinola, Mary, Tai, Xin You, Symmonds, Mkael, Davis Jones, Gabriel, Mura, Sergio, Galloway, Joanne, Hallam, Angela, Chan, Jane Y. C., Koychev, Ivan, Butler, Chris, Geddes, John, Van Der Putt, Rohan, Thompson, Sian, Manohar, Sanjay G., Frangou, Eleni, Love, Sharon, McShane, Rupert, Husain, Masud
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8325256/
https://ncbi.nlm.nih.gov/pubmed/34332638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-021-05404-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados